InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-18 | 2025-11-18 | Rubinstein Samuel | Director | Purchase | 5,000 | $1.41 | $7K | 8,766 | View ↗ | |
| 2025-11-17 | 2025-11-18 | Rubinstein Samuel | Director | Sale | 14.1K | $1.33 | $19K | 3,766 | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenues, net | $30.7M-8.5% | $33.6M+0.6% | $33.4M-7.8% | $36.2M |
| Cost of revenues | $12.8M-10.6% | $14.3M-3.7% | $14.9M+3.5% | $14.4M |
| Gross profit | $17.9M-7.0% | $19.2M+4.1% | $18.5M-15.2% | $21.8M |
| Engineering and product development | $421K-52.3% | $883K-33.0% | $1.3M+28.0% | $1.0M |
| Selling and marketing | $13.1M+5.5% | $12.4M-4.1% | $13.0M-15.3% | $15.3M |
| General and administrative | $10.2M-6.5% | $10.9M+3.7% | $10.5M+4.2% | $10.1M |
| Impairment of goodwill | $0-100.0% | $4.3M+86.9% | $2.3M | $0 |
| Settlement gains | -$1.1M | $0 | — | — |
| Total operating expenses | $22.6M-20.7% | $28.5M+5.2% | $27.1M+2.5% | $26.4M |
| Loss from operations | -$4.7M+49.2% | -$9.3M-7.6% | -$8.6M-85.1% | -$4.6M |
| Interest expense | -$2.0M+7.0% | -$2.1M-28.5% | -$1.6M-77.1% | -$926K |
| Interest income | $410K+69.4% | $242K+4.8% | $231K+159.6% | $89K |
| Other income | $0-100.0% | $864K | $0 | — |
| Other (expense), income net | -$1.5M-54.7% | -$1.0M+56.8% | -$2.3M-176.9% | -$837K |
| Loss before (provision for) benefit from income taxes | -$6.2M+39.1% | -$10.3M+6.1% | -$10.9M-99.1% | -$5.5M |
| (Provision for) benefit from income taxes | -$12K-107.1% | $170K+84.8% | $92K+246.0% | -$63K |
| Net loss | -$6.3M+37.9% | -$10.1M+6.9% | -$10.8M-95.2% | -$5.5M |
| Net loss per share of common stock - basic (in Dollars per share) | -$1K+49.1% | -$3K+14.5% | -$3K-1837.5% | -$160 |
| Net loss per share of common stock - diluted (in Dollars per share) | -$1K+49.1% | -$3K+14.5% | -$3K-1837.5% | -$160 |
| Weighted average shares of common stock outstanding - basic (in Shares) | $4.65B+22.2% | $3.81B+9.0% | $3.49B-89.9% | $34.71B |
| Weighted average shares of common stock outstanding - diluted (in Shares) | $4.65B+22.2% | $3.81B+9.0% | $3.49B-89.9% | $34.71B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
New Peer-Reviewed Publication Confirms Unprecedented Response Rates for STRATA’s Excimer Laser Combined with JAK Inhibitors in Pediatric Vitiligo
STRATA Skin Sciences files to delist, plans to go dark
STRATA Skin Sciences Confirms Nasdaq Delisting
SSKN Stock Falls Despite Meta-Analysis Backs Excimer Laser's Efficacy